Results 211 to 220 of about 28,986 (243)
Some of the next articles are maybe not open access.

Praziquantel

Parasitology Research, 2003
Praziquantel is the drug of choice for the treatment of all forms of schistosomiasis. This review summarizes the main features of the drug, with special attention being given to those aspects that may be of interest to the practicing physician. After a brief mention of the history, the chemistry, the major available brands and their costs, doses and ...
Donato, Cioli, Livia, Pica-Mattoccia
openaire   +2 more sources

Clonorchiasis and Praziquantel

Archives of Internal Medicine, 1985
Human biliary infection with the trematodes Clonorchis sinensis and Opisthorchis viverrini (oriental liver flukes) affects an estimated 20 million people worldwide and is especially prevalent throughout areas of China and southeast Asia. Seven million infections may exist in Thailand alone where 80% of selected populations are infested. 1 United States
Michael A. Kron, Clement C. S. Hsu
openaire   +3 more sources

Schistosomiasis and Praziquantel

Annals of Internal Medicine, 1984
Excerpt To the editor: Last year, in commenting on a review article on praziquantel published in your journal (1), we reported excellent results obtained by treatingSchistosoma haematobiuminfection...
Z. Farid, B. Trabolsi, M. Stek
openaire   +3 more sources

Praziquantel and Schistosomiasis

ChemMedChem, 2010
AbstractReview: 70 refs.
Kareem Khoury, Alexander Doemling
openaire   +4 more sources

Praziquantel resistance

Expert Opinion on Drug Discovery, 2007
Results from infected patients, not cured by multiple doses of praziquantel (PZQ), have been reported from different geographic locations, suggesting that resistance to the drug may be present. This has been coupled with several in vivo (e.g., studies on mice infected with 'resistant isolates') and in vitro tests (e.g., direct application and ...
Sanaa S, Botros, James L, Bennett
openaire   +2 more sources

Praziquantel Therapy for Cysticercosis

Archives of Neurology, 1983
To the Editor. —Both in their editorial entitled "Cysticercosis: An Old Scourge Revisited" (Archives1982; 39:533) and in their article entitled "CNS Cysticercosis" (Archives1982;39:540-544), Grisolia and Wiederholt commented that no specific medical therapy is available for neurocysticercosis. The accompanying article by McCormick et al (Archives1982;
Susan Mates, Joseph H. Friedman
openaire   +3 more sources

Treatment of Cysticercosis With Praziquantel

Archives of Neurology, 1984
To the Editor. —Two recent reports 1,2 have cast some doubts on the efficacy of praziquantel in the treatment of neurocysticercosis. Because this disease is an important neurosurgical problem in Latin America, we wish to report briefly on our experience with this drug.
Jaime G. Gomez   +2 more
openaire   +3 more sources

Praziquantel and Refugee Health

JAMA: The Journal of the American Medical Association, 1984
PRAZIQUANTEL is a new drug that is effective against a broad range of parasitic fluke (Trematoda) and tapeworm (Cestoda) infections. In June 1983, it was approved by the Food and Drug Administration for marketing in the United States. The compound was developed and introduced in the mid-1970s through a joint effort of Bayer AG and E.
Peter M. Schantz, Bruce G. Weniger
openaire   +3 more sources

Home - About - Disclaimer - Privacy